[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602013":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":131,"collaborators":7,"id":133,"slug":134,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":135,"sex":141,"minAge":142,"maxAge":7,"enrollmentInfo":143,"targetDuration":7,"studyType":146,"phases":7,"briefSummary":147,"conditions":148,"keywords":7,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Boris BIENVENU, DR","CONTACT","0140021738","bbienvenu@15-20.fr",[15,30,43,56,69,82,95,105,118],{"facility":5,"status":16,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"RECRUITING","Paris","paris","75012","France","FR",{"type":23,"coordinates":24},"Point",[25,26],2.3488,48.85341,{"lat":26,"lon":25},[29],{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"facility":31,"status":16,"city":32,"state":7,"zip":33,"country":20,"countryCode":21,"cosmosGeoPoint":34,"geoPoint":38,"contacts":39},"CHU Caen Normandie COTE DE NACRE","Caen","14000",{"type":23,"coordinates":35},[36,37],-0.35912,49.18585,{"lat":37,"lon":36},[40],{"name":41,"role":11,"phone":7,"phoneExt":7,"email":42},"Jean Claude QUINTYN, DR","quintyn-jc@chu-caen.fr",{"facility":44,"status":16,"city":45,"state":7,"zip":46,"country":20,"countryCode":21,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"CHU Lyon - Hospices Civils de Lyon","Lyon","69002",{"type":23,"coordinates":48},[49,50],4.84789,45.74906,{"lat":50,"lon":49},[53],{"name":54,"role":11,"phone":7,"phoneExt":7,"email":55},"Juliette ABEILLON, DR","juliette.abeillon@chu-lyon.fr",{"facility":57,"status":16,"city":58,"state":7,"zip":59,"country":20,"countryCode":21,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Hopital Saint Joseph","Marseille","13285",{"type":23,"coordinates":61},[62,63],5.38107,43.29695,{"lat":63,"lon":62},[66],{"name":67,"role":11,"phone":7,"phoneExt":7,"email":68},"Antoine POULER, DR","apoulet@hopital-saint-joseph.fr",{"facility":70,"status":16,"city":71,"state":7,"zip":72,"country":20,"countryCode":21,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"CHU de Montpellier","Montpellier","34295",{"type":23,"coordinates":74},[75,76],3.87635,43.61093,{"lat":76,"lon":75},[79],{"name":80,"role":11,"phone":7,"phoneExt":7,"email":81},"Yves-Marie PERS, PR","ym-pers@chu-montpellier.fr",{"facility":83,"status":16,"city":84,"state":7,"zip":85,"country":20,"countryCode":21,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"CHU Nîmes","Nîmes","30900",{"type":23,"coordinates":87},[88,89],4.35788,43.83665,{"lat":89,"lon":88},[92],{"name":93,"role":11,"phone":7,"phoneExt":7,"email":94},"Olivier GOHIER, DR","OLIVIER.GILLY@chu-nimes.fr",{"facility":96,"status":16,"city":17,"state":7,"zip":97,"country":20,"countryCode":21,"cosmosGeoPoint":98,"geoPoint":100,"contacts":101},"Hopital Fondation de Rothschild","75019",{"type":23,"coordinates":99},[25,26],{"lat":26,"lon":25},[102],{"name":103,"role":11,"phone":7,"phoneExt":7,"email":104},"Clara BOUCHE, DR","cbouche@for.paris",{"facility":106,"status":16,"city":107,"state":7,"zip":108,"country":20,"countryCode":21,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"CHU de Pontchaillou","Rennes","35000",{"type":23,"coordinates":110},[111,112],-1.67431,48.11109,{"lat":112,"lon":111},[115],{"name":116,"role":11,"phone":7,"phoneExt":7,"email":117},"Na'im BEN MILOUD, DR","Naim.BEN.MILOUD@chu-rennes.fr",{"facility":119,"status":16,"city":120,"state":7,"zip":121,"country":20,"countryCode":21,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Hopital Civil \u002F Nouvel Hopital Civil","Strasbourg","67000",{"type":23,"coordinates":123},[124,125],7.74553,48.58392,{"lat":125,"lon":124},[128],{"name":129,"role":11,"phone":7,"phoneExt":7,"email":130},"Lauriana SOLECKI, DR","lauriana.solecki@chru-strasbourg.fr",{"type":132,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100602013","describe-the-progression-of-inflammatory-orbitopathy-and-the-biological-progression-of-patients-receiving-second-line-treatment-100602013",false,"NCT07117981","Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment","Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow","HZN-IIT","Inclusion Criteria:\n\n* Patients aged 18 and older with moderate to severe orbitopathy;\n* Patients followed in endocrinology with the goal of achieving euthyroidism;\n* Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);\n* Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;\n* Patients with a CAS ≥ 3 or CAS \\\u003C3 with moderate to severe orbitopathy (according to EUGOGO);\n* Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment;\n* Patients who are not opposed to the reuse of their health data.\n\nExclusion Criteria:\n\n* Patients who have undergone bone or fat decompression surgery;\n* Patients with severe corneal involvement (Grade B or C; NO SPECS classification);\n* Patients with optic neuropathy (Grade B and C; NO SPECS classification);\n* Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;\n* Patients who have opposed the reuse of their health data.","ALL","18 Years",{"count":144,"type":145},100,"ESTIMATED","OBSERVATIONAL","Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).",[149],"Basedow Disease","2025-08-12",{"date":152,"type":153},"2025-08-15","ACTUAL",{"date":155,"type":153},"2024-11-01",{"date":157,"type":145},"2025-12",{"name":5,"class":6},9]